The Allevi Liver dECM promises the fabrication of liver tissue that has a more representative physiological function. The product uses a combination of a type I collagen Allevi bioink for patterning as well as Xylyx Bio’s highly desired liver-specific TissueSpec® ECM to enhance specialized biological response.
Xylyx Bio products for cell culture are obtained from porcine or human tissue sources and processed to various formats, enabling cell culture models that are significantly more predictive of physiology. Their 3D TissueSpec® ECM hydrogels and scaffolds provide support to cell culture models, facilitating the acceleration of drug discovery, development and tissue regeneration.
“We are thrilled to partner with Allevi and share our expertise in tissue-specific ECM,” stated Andrea Nye, Chief Executive Officer at Xylyx Bio. “Recognizing the importance of the native cellular microenvironment, Xylyx Bio harnesses the body’s innate biology in the form of tissue-specific extracellular matrix. By sourcing extracellular matrix from native organs and tissues, Xylyx produces tissue-specific substrates that comprise both the mechanical properties and complex ratios of ECM components specific and unique to each tissue and organ type.”
Founded in 2014, Allevi claims that its “mission is to provide users the ability to design, engineer, and manufacture 3D tissue.” To deliver important building blocks and provide users with the best experience possible to drive new scientific discoveries, Allevi is hopeful that the new dECM bioink will provide scientists a revolutionary approach that allows scientists to print 3D tissue structures with biochemical and mechanical features inherent in human physiology.
[Images: Allevi and Xylyx Bio]
Xylyx Bio’s Co-founder and Chief Strategy Officer, John O’Neil, added that a “deeper understanding of the comprehensive nature of tissues and cells and their interaction with the cellular microenvironment – that is, the extracellular matrix – holds great promise to lead to a paradigm shift in 3D bioprinting, allowing researchers to study physiologic activity of cells in vitro towards a better understanding of disease and development of more effective drugs and treatments.”
You May Also Like
Prodways Q2 Revenues Increase, Machine Sales Up 100%
Prodways (PWG.PA) reported a 54% revenue increase year over year for its second quarter in 2021 as the global economy recovers from the Covid-19 pandemic. Driven by the recovery of...
Materialise Reports Higher Profits for Q2 2021, Revenue Up
After a pandemic-laden 2020, Materialise (Nasdaq: MTLS) is set to benefit in 2021 owing to a solid recovery from its medical and manufacturing segments. The Belgian software and 3D printing...
2nd 3D Printing Facility Unveiled by Burloak Technologies
Burloak Technologies has unveiled its second 3D printing facility in North America. The Camarillo, California site adds 25,000-square-foot of production capabilities to their already 65,000-square-foot facility located in Ontario, Canada....
SPACs Everywhere: 3D Printing Companies Going Public in 2021
The SPAC trend that revolutionized the IPO market in 2020 continues in 2021. Blank-check mergers through special purpose acquisition companies (SPACs) have surged globally to a record $170 billion in...
View our broad assortment of in house and third party products.